ViMed reported record third-quarter revenue of $80.7 million and net income of $4.6 million, raised full-year revenue guidance to $316 million to $320 million, and plans maternal health expansion at two states per quarter.
VMD · Viemed Healthcare, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 32%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 4
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Viemed Healthcare reported quarterly revenue of $80.7 million, up 12.2%, and net income of $4.7 million, up 31.6%, for the three months ended September 30, 2026.
Viemed Healthcare reported record third-quarter net revenue of $80.7 million, up 12.2% year over year, and raised full-year revenue guidance to $316 million to $320 million while narrowing Adjusted EBITDA guidance to $64 million to $66 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. ViMed delivered record revenue, stronger sequential earnings, expanding sleep volumes, ventilation revenue growth, and a planned maternal health rollout; it also raised the revenue guidance floor and lowered its capital-expenditure outlook while reducing debt and repurchasing shares. Offsetting these gains were lower gross and year-over-year Adjusted EBITDA margins, reduced cash conversion and higher audit costs, softer period-end ventilation patients, a lower Adjusted EBITDA guidance ceiling, and time needed for maternal health markets to mature.
- + PAP therapy and sleep resupply patient volumes grew strongly year over year and sequentially.
- + Ventilator rental revenue increased 7.4% year over year and 2.9% sequentially to $37.5 million, supported by higher average patient volumes. new
- + The maternal health rollout is expected to expand at a cadence of two additional states per quarter beginning in the fourth quarter. new
- + ViMed reduced debt and returned capital through share repurchases during the quarter. new
- − Gross margin declined year over year and sequentially as sales and services increased to 32% of revenue. new
- − Adjusted EBITDA margin was 21.1%, below 22.4% a year earlier. new
- − Industry audit activity is increasing administrative and professional costs and can extend payment timelines. new
- − The period-end ventilator patient count declined sequentially, and management described patient-count trends as wobbly. new
- − The upper end of full-year Adjusted EBITDA guidance was lowered.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 13.7M | the quarter ended June 30, 2026 | — |
|
|
|||
| Average buyback price per share | $9.65 | the second quarter of 2026 | — |
| Free cash flow non-GAAP | 34.4M | the trailing twelve months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 60.78M
-31.55M Purchase of property and equipment
+5.2M Proceeds from sale of property and equipment
= Free cash flow 34.43M
|
|||
| Net cash provided by operating activities | 60.8M | the trailing twelve months ended June 30, 2026 | — |
| PAP Therapy Patients | 37,825 | Q2 2026 | — |
|
|
|||
| Shares repurchased and cancelled | 530,802 | the second quarter of 2026 | — |
| Sleep Resupply Patients | 37,035 | Q2 2026 | — |
|
|
|||
| Total number of shares (or units) purchased | 535,260 | the three months ended June 30, 2026 filing | — |
| Ventilator patients | 12,635 | the quarter ended 6/30/26 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VMD
this stock
Viemed Healthcare, Inc.
|
$326.26M | +15.9% | +20.5% | 22.7 | 4.0% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VMD | -5.5% | -13.2% | -11.4% | -11.0% | +15.9% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | 0.0% | -6.9% | -5.8% | -5.7% | +10.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.